Skip to content

Author

Kelly N. Fitzgerald

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

85 Phase 3 LITESPARK-033 (NCT07227402) Study of Belzutifan Plus Zanzalintinib Versus Cabozantinib for Recurrent Clear Cell Renal Cell Carcinoma During or After Adjuvant Anti–PD-(L)1 Therapy

Abstract Background Adjuvant pembrolizumab is the standard of care for patients with renal cell carcinoma (RCC) at increased risk for recurrence after nephrectomy. However, treatment options are needed following adjuvant anti–PD-(L)1 therapy because none of the currently available treatments for advanced RCC were evalu...

T. Choueiri, T. Powles, M. Voss et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.